OS Therapies: OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
OS Therapies reported 71.2% 3-year survival for OST-HER2-treated patients vs. 45.8% in historical controls (p=0.002). The company received $3.15M in VAT refunds and anticipates $7.2M more. It plans to submit regulatory applications for OST-HER2 in Q4 2026. According to the company, OST-HER2 has received multiple designations from FDA and EMA.
How this was made
The 30-second read
Why it matters
The interim survival data strengthens the case for accelerated approval and may trigger a re‑rating by analysts.
Market read
First disclosure of pivotal Phase 2b data for a rare pediatric cancer therapy, likely to move the stock and related biotech peers.
What to watch
Pending VAT refunds and tax credits could affect cash runway, while PRV valuation remains uncertain.
Background
OS Therapies is a clinical‑stage oncology company developing Listeria‑based gene‑edited immunotherapies for osteosarcoma.
Ticker impact
OS Therapies announced statistically significant interim 3-year overall survival data from its Phase 2b OST-HER2 trial, showing 71.2% vs 45.8% historical control.
Potential upside as investors price in accelerated approval prospects and future PRV sale.
Phase 2b data is a material catalyst for a clinical‑stage biotech; market typically reacts sharply to positive survival outcomes.
Market effects
Boosts confidence in Listeria‑based immunotherapies and may lift peer biotech stocks in oncology.
Positive for US biotech sector; UK and EU regulators may view data favorably for conditional approvals.
Highlights emerging gene‑edited cancer therapies, potentially influencing global biotech investment flows.
Counterpoint
Skeptics may question durability of survival benefit given small sample size and reliance on historical controls.
Key entities
- CompanyOS Therapies, Inc.
Developer of OST-HER2 immunotherapy.
- ExecutiveDr. Craig Eagle
Chief Medical Advisor providing commentary on trial results.
